The majority of PCOS are overweight or obese (OW/OB) with increased infertility and risk of pregnancy complications. Evidences show that in PCOS, metformin and exenatide have impact on insulin resistance and body weight with seldom information about pregnancy and its outcome. This study was designed directly to compare the effect of two treatments on pregnancy rate and outcomes in OW/OB PCOS. This prospective clinical trial randomized 160 OW/OB PCOS with infertility, without diabetes into metformin and exenatide treatment for the first 12 weeks. Afterward, all were treated with metformin alone until week 52. If patients failed spontaneous pregnancy during the second 12 weeks, assisted reproduction technique (ART) could be offered until week 52. The spontaneous and total pregnancy rates were recorded within 52 weeks. Pregnancy outcomes were followed until the deliveries. Baseline characteristics were similar between two groups. At week 24, higher spontaneous pregnancy rate was observed in exenatide group, although at week 52, the total pregnancy rates were similar between two groups. Meanwhile, no significant difference of pregnancy outcomes was implicated between two groups (Table 1). In OW/OB PCOS, 12 weeks exenatide treatment had improved spontaneous pregnancy rate compared with metformin treatment, without benefit effects on total pregnancy rate and overall pregnancy outcomes.
R. Li: None. S. Zheng: None. T. Mai: None. J. Xue: None. Y. Zhang: None.
National Natural Science Foundation of China (81200607)
© 2020 by the American Diabetes Association
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.